Risk factors for coronary disease: The time for a paradigm shift?

被引:11
作者
Dominiczak, MH [1 ]
机构
[1] Gartnavel Royal Hosp, Dept Biochem, Glasgow G12 0YN, Lanark, Scotland
关键词
cardiovascular risk; troponin I; troponin T; C-reactive protein; Fibrinogen Adult Treatment Panel III; triglyceride-rich lipoproteins;
D O I
10.1515/CCLM.2001.147
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Risk stratification is a key element of clinical management not only in the primary and secondary prevention, but also during the acute stages of cardiovascular disease. The current risk assessment algorithms in primary prevention are based on established risk factors: gender and age, cigarette smoking, the presence of hypertension and diabetes mellitus, and serum concentrations of total cholesterol, low-density lipoprotein (LDL)-cholesterol and high-density lipoprotein-cholesterol. However, many individuals who are assessed as "low risk" on the basis of traditional risk factors, still develop cardiac events. This article addresses current issues relevant to the assessment of cardiovascular risk. It emphasizes the potential importance of disturbed energy supply for atherogenesis, by introducing the concept of fuel transport (chylomicron, VLDL, and remnants) and overflow (LDL) pathways of lipid metabolism. It highlights the present lack of routine methods to monitor the fuel transport pathway. It considers the measurements of serum C-reactive protein and plasma fibrinogen as new additions to the cardiovascular risk factor profiles. Finally, risk stratification based on the traditional and the new risk factors is linked to that based on the markers of acute myocardial damage such as cardiac troponin I or troponin T. It is concluded that the combined use of the markers of myocardial damage and the "new" cardiovascular risk factors is the way ahead for the assessment of cardiovascular risk.
引用
收藏
页码:907 / 919
页数:13
相关论文
共 106 条
[1]   Myocardial infarction redefined -: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Hoppe, U ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
de Werf, FV ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
EUROPEAN HEART JOURNAL, 2000, 21 (18) :1502-1513
[2]   Myocardial infarction redefined -: A consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Alto, P ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
Van de Werf, F ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) :959-969
[3]  
[Anonymous], 1994, CIRCULATION
[4]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[5]  
Apple FS, 2001, CLIN CHEM, V47, P377
[6]   Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study [J].
Aronow, HD ;
Topol, EJ ;
Roe, MT ;
Houghtaling, PL ;
Wolski, KE ;
Lincoff, AM ;
Harrington, RA ;
Califf, RM ;
Ohman, EM ;
Kleiman, NS ;
Keltai, M ;
Wilcox, RG ;
Vahanian, A ;
Armstrong, PW ;
Lauer, MS .
LANCET, 2001, 357 (9262) :1063-1068
[7]   Coronary heart disease: Reducing the risk - The scientific background to primary and secondary prevention of coronary heart disease a worldwide view [J].
Assmann, G ;
Cullen, P ;
Jossa, F ;
Lewis, B ;
Mancini, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (08) :1819-1824
[8]   ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].
AUSTIN, MA ;
KING, MC ;
VRANIZAN, KM ;
KRAUSS, RM .
CIRCULATION, 1990, 82 (02) :495-506
[9]   Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease [J].
Beller, GA ;
Zaret, BL .
CIRCULATION, 2000, 101 (12) :1465-1478
[10]   Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina [J].
Benamer, H ;
Steg, PG ;
Benessiano, J ;
Vicaut, E ;
Gaultier, CJ ;
Aubry, P ;
Boudvillain, O ;
Sarfati, L ;
Brochet, E ;
Feldmann, LJ ;
Himbert, D ;
Juliard, JM ;
Assayag, P .
AMERICAN HEART JOURNAL, 1999, 137 (05) :815-820